Avidity Partners Management LP Alpine Immune Sciences, Inc. Transaction History

Avidity Partners Management LP

$1.63 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $20.9 Million - $48.9 Million	1,174,700 New	1,174,700 $46.6 Million
Q3 2023 Nov 14, 2023	SELL	$10.13 - $13.98 $4.06 Million - $5.61 Million	-401,220 Reduced 37.9%	657,280 $7.53 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $471,960 - $821,790	69,000 Added 6.97%	1,058,500 $10.9 Million
Q1 2023 May 15, 2023	SELL	$7.0 - $8.75 $270,900 - $338,625	-38,700 Reduced 3.76%	989,500 $7.64 Million
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $161,320 - $217,560	29,600 Added 2.96%	1,028,200 $7.56 Million
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $241 - $328	35 Added 0.0%	998,600 $7.19 Million
Q2 2022 Aug 15, 2022	SELL	$6.71 - $9.52 $1.4 Million - $1.98 Million	-208,435 Reduced 17.27%	998,565 $8.5 Million
Q1 2022 May 16, 2022	SELL	$6.41 - $13.89 $884,580 - $1.92 Million	-138,000 Reduced 10.26%	1,207,000 $10.8 Million
Q4 2021 Feb 14, 2022	SELL	$10.41 - $13.95 $6.11 Million - $8.19 Million	-587,000 Reduced 30.38%	1,345,000 $18.6 Million
Q3 2021 Nov 15, 2021	BUY	$8.19 - $11.31 $3.58 Million - $4.94 Million	437,000 Added 29.23%	1,932,000 $20.6 Million
Q2 2021 Aug 16, 2021	SELL	$8.81 - $15.03 $140,960 - $240,480	-16,000 Reduced 1.06%	1,495,000 $13.5 Million
Q1 2021 May 17, 2021	BUY	$10.02 - $13.92 $2.64 Million - $3.66 Million	263,000 Added 21.07%	1,511,000 $16 Million
Q4 2020 Feb 16, 2021	BUY	$7.42 - $15.96 $3.25 Million - $6.99 Million	438,000 Added 54.07%	1,248,000 $15.7 Million
Q3 2020 Nov 16, 2020	BUY	$7.15 - $11.5 $5.79 Million - $9.32 Million	810,000 New	810,000 $7.12 Million

Others Institutions Holding ALPN

# of Institutions

Shares Held

56.2K

Call Options Held

Put Options Held

View Full List

About ALPINE IMMUNE SCIENCES, INC.

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

More about ALPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Account